We present a case of papillary thyroid cancer (post-thyroidectomy status) on regular treatment with suppressive Levothyroxine therapy. On follow-up at 6 months after radioactive iodine ablation for remnant thyroid tissue, her thyroglobulin, and anti-thyroglobulin levels were 0.06 ng/ml and 670 IU/ml, respectively. Low-dose whole-body I-131 scan was negative. To look for the cause of isolated increased anti-thyroglobulin level, a whole-body 18F-FDG PET/CT was done which revealed multiple FDG-avid lytic skeletal lesions suggestive of metastases. For confirmation of diagnosis, 18F-FDG PET/CT-guided metabolic biopsy was done, which revealed Langerhans’ cell histiocytosis on histopathological examination.
This is a preview of subscription content, log in to check access.
Compliance with Ethical Standards
Conflict of Interest
Dharmender Malik, Rajender Kumar Basher, Bhagwant Rai Mittal, Gaurav Parkash, Amanjit Bal, and Anish Bhattacharya declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
The institutional review board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164–7.CrossRefPubMedGoogle Scholar
Mihailovic J, Stefanovic L, Malesevic M. Differentiated thyroid carcinoma with distant metastases: the probability of survival and its predicting factors. Cancer Biother Radiopharm. 2007;22:250–5.CrossRefPubMedGoogle Scholar
Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery. 2008;143:35–42.CrossRefPubMedGoogle Scholar
Lee J, Soh E-Y. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis. Ann Surge. 2010;251:114–9.CrossRefGoogle Scholar
Showalter TN, Siegel BA, Moley JF, Baranski TJ, Grigsby PW. Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm. 2008;23:655–60.CrossRefPubMedGoogle Scholar
Borschitz T, Eichhorn W, Fortner C, Hansen T, Schad A, Schadmand-Fischer, et al. Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma. Thyroid. 2010;20:93–8.CrossRefPubMedPubMedCentralGoogle Scholar
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.CrossRefPubMedGoogle Scholar
Badalian-Very G, Vergilio J-A, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–23.CrossRefPubMedPubMedCentralGoogle Scholar
Lian C, Lu Y, Shen S. Langerhans cell histiocytosis in adults: a case report and review of the literature. Oncotarget. 2016;7:18678–83.PubMedPubMedCentralGoogle Scholar
Patten DK, Wani Z, Tolley N. Solitary Langerhans histiocytosis of the thyroid gland: a case report and literature review. Head Neck Pathol. 2012;6:279–89.CrossRefPubMedGoogle Scholar
Pusztaszeri MP, Sauder KJ, Cibas ES, Faquin W. C. Fine-needle aspiration of primary Langerhans cell histiocytosis of the thyroid gland, a potential mimic of papillary thyroid carcinoma. Acta Cytol. 2013;57:406–12.CrossRefPubMedGoogle Scholar
Yaˇgcı B, Kandemir N, Yazıcı N, Yalçın B, Varan A, Akyü C, et al. Thyroid involvement in Langerhans cell histiocytosis: a report of two cases and review of the literature. Eur J Pediatr. 2007;166:901–4.CrossRefGoogle Scholar